Target trial emulation of physical activity and cardiovascular disease risk: What is impact of the exposure assessment method?

Matthew Ahmadi[1,2,3]*, Borja del Pozo Cruz[4]*, Raaj Biswas[2,3,5], Nicholas Koemel[1,2,3], Armando Teixeira-Pinto[3], Dot Dumuid[6], Marla Beauchamp[7], Joanne McVeigh[8], Mark Hamer[9], Emmanuel Stamatakis[1,2,3]

Mackenzie Wearables Research Hub

Charles Perkins Centre, University of Sydney

School of Health Sciences, Faculty of Medicine and Health, University of Sydney

Department of Sport Sciences, Faculty of Medicine, Health, and Sports, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, 28670, Spain

Snow Vision Accelerator, University of Sydney

Alliance for Research in Exercise, Nutrition and Activity, Allied Health & Human Performance, University of South Australia, Adelaide, South Australia, Australia

School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada

Curtin School of Allied Health, Curtin University, Perth, Western Australia

Institute of Sport Exercise and Health, Division of Surgery and Interventional Sciences, University College London, United Kingdom

*Joint first author

Corresponding author:
Emmanuel Stamatakis

Address for correspondence:
Hub D17, Charles Perkins Centre L6 West, the University of Sydney, New South Wales, Australia.
Email address: emmanuel.stamatakis@sydney.edu.au

Word Count: Abstract: 414; Main text: 3311 words; 3 Tables; 1 Figure; 1 Supplemental Table; 11 Supplemental Figures

Abstract

Background: Target trial emulation (TTE) designs provide a framework for
strengthening causal inference in observational research, but it is unknown how
vulnerable they are to substantial error when the emulated intervention (exposure)
measurement is imprecise. In physical activity epidemiology specifically, correcting
for confounding via TTE designs but not addressing the large measurement errors
arising from self-reports (e.g. questionnaires, which typically capture partial
behavioural accounts with very low precision) creates uncertainty about possible
dominance of type 2 error biases arising from such novel designs. High-resolution
wearables-based methods capture most movement, providing an assessment of
physical activity behaviour with substantially less, empirically verified, measurement
error. No study has examined how physical activity measurement method influences
causal inference in TTE studies.

Objectives:

We applied TTE methodology to sub-samples of the UK Biobank cohort with repeat
exposure measurements, to compare the effects of an emulated physical activity
intervention on incident CVD risk, when the physical activity exposure was quantified
using self-report vs. wearable devices.

Methods:

The emulated randomized controlled trial identified physically inactive adults (<150
moderate-to-vigorous physical activity (MVPA) mins/week) who had repeat
assessments for wearable and self-reported physical activity. At re-examination,
participants were categorised into intervention (adopted the current recommendation
of ≥150 MVPA mins/week) or control (remained physically inactive) groups.
Participants in each group were propensity score-matched to balance lifestyle
behaviours, demographic, and health factors. Cumulative risk for CVD incidence was
assessed through cumulative risk curves, hazard ratios, risk ratios, using Fine-Gray
subdistribution and Poisson regression models.

Results:

The wearables analytic sample included 490 participants (245 per arm; mean
incident CVD follow-up 4.4 years), and the self-report sample included 11,302
participants (5,651 per arm; mean follow-up 6.3 years). In wearables assessments,

guideline-adherent participants had markedly lower cumulative CVD risk (cumulative

risk = 8.0% vs. 17.0%; hazard ratio [95%CI] = 0.59 [0.36, 0.98]; relative risk = 0.45

[0.28, 0.72]). In contrast, self-report assessments showed near-identical risk

trajectories for intervention and control groups (cumulative risk = 21.6% vs. 21.2%;

hazard ratio = 0.98 [0.89, 1.08]; relative risk = 0.92 [0.84, 1.00]). Matching the self-

report sample to the wearables sample for lifestyle, demographic, and health factors

confirmed these findings.

Conclusion:

Reliance on self-reported measures of physical activity in TTE studies may obscure

emulated intervention effects due to non-differential misclassification, increasing

considerably risk of Type II error. Exposure assessment using wearable devices may

be essential for valid causal inference in TTE studies of physical activity and CVD

risk. Future TTE studies of physical activity exposures should prioritise objective

measurements to avoid biased inferences that could affect public health policy and

guidelines.

Introduction

Randomized controlled trials (RCTs) are widely regarded as the gold standard for causal inference in evaluating intervention effects. By randomly assigning participants to treatment or control groups, RCTs minimise differences between study arms aside from the intervention itself, thus allowing any observed differences in outcomes to be attributed causally to the treatment. However, the logistics, costs, and ethical concerns associated with extended follow-up, such as hospitalization and mortality, often limit the feasibility of traditional RCTs[1] [2]. Currently, physical activity guidelines are developed using almost exclusively observational prospective studies, the large majority of which used self-reported measures to quantify physical activity[3-5].

In scenarios where RCTs cannot be practically conducted, target trial emulation offers a rigorous framework for causal inference based on observational data[6]. This approach involves explicitly designing an observational analysis to mirror the protocol of a hypothetical RCT that addresses the causal research question at hand. The goal is to preserve the internal validity of RCTs while leveraging real-world data, thereby enhancing transparency and mitigating key biases often associated with observational research[7].

Target trial emulation encompasses a two-step process[8]. First, investigators specify a detailed protocol (including eligibility criteria, treatment strategies, treatment assignment procedures, timing of follow-up, outcomes, causal estimands, and analysis plans) that defines the ideal RCT to answer the research question. Second, the components of this protocol are then applied to observational data: eligible individuals are identified, treatment strategies are assigned, follow-up and censoring periods are delineated, and analytic techniques (such as propensity score matching or inverse probability of treatment weighting) are employed to minimise baseline differences in potential confounders between groups except for the treatment.

While target trial emulation designs have gained momentum in recent years[9] and are advancing observational population study designs[10-13] by systematically addressing biases that contribute to Type I error (false statistically significant effects). They remain vulnerable to Type II error (false statistically non-significant effects) when the intervention target variable is measured imprecisely. For target trial emulation studies

to yield valid causal inferences, accurate and unbiased measurement of the
intervention is crucial[14]. This concern is especially pronounced in observational
physical activity research, where reliance on self-reported data (e.g. questionnaires)
introduces substantial reporting bias and non-differential misclassification error[15].
Self-reported measures of physical activity capture partial behavioural accounts
(mostly leisure-time activities lasting for at least 10-15 minutes) with low precision[16-
18]. When such misclassification occurs, target trial emulation frameworks may be
prone to Type II error, which may artificially nullify findings despite true benefits of
physical activity. It is unclear if the markedly low effects sizes reported by the early
application of TTE designs in self-reported physical activity research[19-21] are signs of
such Type II error. In contrast, wearable devices are not susceptible to self-report
bias and when matched with high resolution machine learning based methods
provide greater accuracy in quantifying physical activity continuously with high
measurement granularity[22 23].

We used a target trial framework to mirror an RCT among physically inactive adults
that estimated the effects of increasing physical activity to meet guidelines[3] versus
remaining physically inactive on incident CVD risk. To evaluate the impact of
measurement type on causal inference estimates, we compared causal effects on
CVD risk from self-report and wearables-based physical activity.

Methods

Comprehensive descriptions of the UK Biobank design have been published
previously [24]. In summary, between 2006 and 2010, about 500,000 adults aged 40–
69 years from England, Scotland, and Wales were enrolled in the large-scale
prospective cohort (overall response rate 5.5%).

Physical activity measurement

Self-reports

Baseline self-reported physical activity was measured between 2006-2010 when
participants underwent a touchscreen-based short-form International Physical
Activity Questionnaire (IPAQ)[25] assessment. Participants reported their frequency
and duration per week of walking, and moderate and vigorous intensity activity
lasting for at least 10 continuous minutes[25]. A total of 394,110 participants provided
baseline physical activity self-report data. Physical activity was expressed as

metabolic equivalent of task (MET) minutes using standard IPAQ scoring procedures, which assign MET values of 3.3 for walking, 4.0 for moderate intensity activity, and 8.0 for vigorous intensity activity. Weekly MET-minutes for each activity type were calculated by multiplying the MET value by the weekly frequency and duration (MET value × days per week × minutes per day) and summed to obtain total physical activity volume. The IPAQ threshold of 600 MET-min/week corresponds to the guideline recommendation of 150 minutes of MVPA per week. Among the participants with baseline physical activity data, 64,382 also had re-examination data.

The exposure window in the TTE analyses was defined as the time from physical activity re-examination (time zero) to CVD incidence or censoring, whichever came first, i.e. for self-report physical activity this began between 2012-2019.

Wearables

A subgroup of 103,712 participants later took part in the main accelerometer substudy conducted between 2013 and 2015. Each person was mailed an Axivity AX3 wrist-worn triaxial accelerometer (sampling at 100 Hz) and instructed to wear it continuously on the dominant wrist for seven consecutive days.

For wearables-based physical activity, the exposure window began between 2017-2019, when 5,063 individuals were invited to repeat the accelerometer assessments[26], using a stratified sampling by sex and 10-year age bands. Participants were scheduled to complete four monitoring sessions approximately three months apart, with flexibility allowing missed early sessions to be compensated later. Among those invited, 3,208 individuals (63%) agreed to participate. All data collection procedures were identical to those used in the baseline accelerometry data collection.

For the wearable devices, the acceleration signal was calibrated and non-wear periods were identified according to standard procedures[27]. Monitoring days were considered valid if wear time was greater than 16 hours, and to be included in the analysis participants were required to have at least four valid monitoring days, with at least one of those days being a weekend day. MVPA was assessed using a 2-stage Random Forest physical activity intensity classifier schema (accuracy = 84% and F-score= 0.83)[28]. We have described the 2-stage schema in detail previously[29], and we

144 have also appended it as **Supplemental Text 1**. In brief, Physical activity intensity
145 was classified with an accelerometer-based activity machine learning scheme
146 covering sedentary, light, moderate, and vigorous intensity physical activity. The 2-
147 stage activity scheme uses features in the raw acceleration signal to identify and
148 quantify time spent in different activity types[30] and then intensities in 10s windows.

Target trial emulation sample

Framework

A target trial emulation approach enables the use of observational data to emulate a
"target" trial (i.e., the RCT that would have been conducted, were it possible to do
so), with exposures framed as hypothetical interventions over a predefined
treatment/exposure period[8]. We emulated a target trial in which physically inactive
participants at baseline were assigned to one of two groups: an intervention group
that met physical activity guidelines at follow-up, or a control group that remained
physically inactive and did not meet guidelines at follow-up (**Table 1**). This design
conceptualises the "intervention" as the initiation of guideline-concordant physical
activity among previously inactive adults.

Eligibility

To operationalise this target trial design, we included participants from the UK
Biobank cohort who had at least 2 assessments (baseline and follow-up) of
wearables or self-report physical activity data. Eligibility was restricted to physically
inactive adults at baseline (i.e., not meeting physical activity guidelines at baseline
assessment), ensuring that all participants were "entering into" the hypothetical
intervention at time zero. Additional information for the target trial emulation design
and timeline comparison of the "target trial" and "trial emulation" is provided in
Supplementary Text 2.

Emulated intervention

Participants were classified into the intervention group based on their physical
activity status at re-examination (time zero). Those who had adopted sufficient
physical activity (≥150 MVPA-minutes/week) were assigned to the intervention
group, while those who remained physically inactive were assigned to the control
group. This operationalisation mirrors the "target trial" design described in Table 1,

where the causal question of interest is whether initiating guideline-concordant
physical activity reduces CVD incidence compared with remaining inactive.

Cardiovascular disease ascertainment

Participant data was linked with electronic health records for mortality through the
National Health Service (NHS) Digital of England and Wales or the NHS Central
Register and National Records of Scotland up through November 30th, 2022.
Inpatient hospitalisation data were provided by either the Hospital Episode Statistics
for England (October 31st, 2022), the Patient Episode Database for Wales (May 31st,
2022), or the Scottish Morbidity Record for Scotland (August 31st, 2022). CVD was
defined as major CVD incidence including ischaemic heart disease, pulmonary heart
disease, heart failure, stroke, and hypertensive heart disease.

Matching participants for lifestyle and health factors

After categorising participants according to whether they met physical activity
guidelines (intervention) or not (control), we implemented propensity score matching
to balance potential confounding lifestyle and health characteristics between groups.
Propensity scores were estimated using a logistic regression model that included the
following covariates: age, sex, education, ethnicity, fruit and vegetable consumption,
alcohol consumption, smoking status, sleep duration, screen time, medication use
(antihypertensive, antidiabetic, and lipid-lowering medication), prevalent
cardiovascular disease, prevalent cancer, and parental history of cardiovascular
disease or cancer.

To ensure differences in outcomes can more plausibly be attributed to effects of the
exposure. This approach simulates the exchangeability of randomised groups by
ensuring that, at study entry, the distribution of lifestyle, demographic, and health
characteristics is similar between the intervention and control groups. Matching on
these lifestyle, demographic, and health characteristics accounts for measured
confounding and strengthens causal inference from observational data in the target
trial emulation framework. **Supplemental Figure 1** displays a Love plot showing the
standardized mean differences for these covariates between the intervention and
control groups, both before matching (full sample) and after matching (inclusion of
only participants with similar lifestyle, demographic, and health characteristics

between the two groups). Based on standard practice, standardised mean
differences with a value less than 0.1 is indicative of negligible imbalance[31].

Statistical analysis

We used Cox proportional hazard regression models with Fine-Gray subdistribution
to address competing risk, which allows a more accurate estimation of the
cumulative incidence of the outcome in the presence of a competing event that
precludes the occurrence of the event of interest (CVD hospitalisation or death). The
proportional hazards assumption was assessed using Schoenfeld residuals and no
violations were observed. To mirror the analyses traditionally used in RCT's, in
addition to hazard ratios, we generated cumulative risk curves. We also used
modified Poisson regression models with robust standard errors to estimate risk
ratios and risk differences. The control group was used as the reference, when
applicable. Propensity score matching was performed using nearest neighbour
matching with a 1:1 ratio and a caliper of 0.05 standard deviations. Balance between
groups was assessed using standardised mean differences. Participants were
excluded from analyses if they had missing data.

In a supplemental analysis, we matched the self-report sample to the wearables
sample on lifestyle, demographic, and health characteristics to create comparable
cohorts. This allowed us to assess whether differences in CVD risk estimates
between self-report and wearables-based physical activity measurements were
attributable to exposure assessment method rather than differences in sample
characteristics. We did further analyses among adults ≥60 years to mirror
interventions targeting older populations[32], and censoring follow up at 2 years to
approximate medium term CVD prevention trials[33].

If significant risk differences were observed, we conducted the following sensitivity
analyses to assess the robustness: 1) exclusion of participants with prevalent CVD
prior to time-zero, 2) exclusion of participants with an event in the first year of follow-
up, 3) using the upper recommendation (300 minutes/week of MVPA) of the physical
activity guidelines to delineate our control and intervention groups, 4) using cause-
specific hazard model instead of Fine-Gray subdistribution, and 5) using a negative
control outcome of deaths or hospitalisations from accidents (excluding cycling, self-
harm, and falls incidence), an outcome that does not have an explicit mechanistic

link to physical activity to assess residual confounding. We used R 4.2.1 (R Core

Team, 2017) to conduct all analyses. This study was reported in accordance with the

TARGET guidelines[34] (**TARGET Supplemental Table**).

Results

Our analytic sample for the wearables sample included 490 participants (245 in the

control and 245 in the intervention group; **Supplemental Figure 2**) with a mean (SD)

follow-up time of 4.4 (1.02) years and 63 CVD incidence events. Our self-report-

based sample included 11,302 participants (5,651 in the control and 5,651 in the

intervention group; **Supplemental Figure 3**) with a mean (SD) follow-up time of 6.3

(2.4) years and 1,642 CVD incidence events. **Table 2** displays the participant

characteristics for both analytic samples.

Figure 1 presents the cumulative risk for CVD incidence for the intervention

(meeting physical activity guidelines at re-examination) and control (not meeting

physical activity guidelines at re-examination) participants. In the wearables

assessed physical activity analysis, participants in the control had a higher

cumulative risk over 5 years of follow-up compared to the treatment participants.

Specifically, at the end of follow-up participants in the control had a cumulative risk of

16.99% [95% CI = 12.83%, 20.95%] and participants in the treatment group had a

risk of 8.06% [5.69%, 11.81%]. In contrast, self-reported physical activity showed

minimal differentiation in cumulative risk between control and treatment participants.

The cumulative risk increased at a similar rate for both groups, with the control group

reaching 21.56% [20.10%, 22.99%], and the treatment group reaching 21.16%

[19.64%, 22.64%] over 10 years of follow-up **(Table 3).**

Analyses using the control group as the reference showed that participants in the

intervention group **(Table 3),** as measured by wearables, had a hazard ratio of 0.59

[0.36, 0.98], while those based on self-report had a hazard ratio of 0.98 [0.89, 1.08].

The corresponding relative risk estimates were 0.45 [0.28, 0.72] for wearables and

0.92 [0.84, 1.00] for self-report. The %risk difference was –2.59% [–4.89%, -0.29%]

for wearables compared to –1.24% [–3.23% to 0.75%] for self-reported assessment.

In our supplemental analyses, matching lifestyle, demographic, and health

characteristics of the self-report sample to the wearables sample showed no

difference in cumulative CVD risk between intervention and control groups for the

self-report sample (**Supplemental Figure 4**). Descriptive information for these
participants is shown in **Supplemental Table 1** alongside the wearables sample**.**
Among adults ≥60 years and in analysis censoring follow up at 2 years, the
wearables sample continued to show lower cumulative risk in the intervention group,
wider confidence intervals relative to our main analysis, whereas cumulative risk
estimates remained similar between intervention and control groups in the self-report
sample (**Supplemental Figures 5 and 6**).

Sensitivity analyses in the wearables sample, including excluding events in the first
year of follow-up, excluding participants with prevalent CVD, and redefining the
intervention using the upper guideline recommendation (300 mins/week of MVPA)
showed results that were consistent with the main analysis (**Supplemental Figures**
7-9). Cause-specific hazard models (**Supplemental Figure 10**) showed risk patterns
comparable to the primary Fine-Gray analysis, and the negative control outcome
(Supplemental Figure 11) exhibited risk patterns that differed from the main
outcome, suggesting that residual confounding had minimal impact on our
observations.

Discussion

In this target trial emulation of a guideline-based physical activity intervention, we
observed markedly different causal estimates depending on how the emulated
exposure was measured. When physical activity was quantified using wearable
devices, adopting guideline levels of activity was associated with substantially lower
cumulative incidence of cardiovascular disease. In contrast, when the same
intervention was defined using self-reported physical activity, risk trajectories for
intervention and control groups were nearly identical, yielding null or near-null
estimates. Our findings suggest that exposure measurement error, rather than lack
of a true causal effect, may be a dominant source of bias in target trial emulation
studies of physical activity.

Target trial emulation is increasingly used to strengthen causal inference in
observational research by explicitly addressing biases such as confounding and
immortal time bias[6 35]. However, our results show that even when these sources of
Type I error are carefully mitigated, causal inference remains highly vulnerable to
Type II error when the emulated intervention is measured imprecisely. In physical

activity epidemiology, self-reported instruments are known to capture only partial
behavioural domains, rely on long-term recall, and exhibit substantial random error
and non-differential misclassification[15][36]. Under these conditions, true intervention
effects may be systematically attenuated toward the null, even within well-specified
target trial emulation frameworks.

This perspective also helps to provide important context for interpreting previous
target trial emulation studies of physical activity. Recent target trial emulations for
COPD[37], cancer[20][21][38], mental health[39][40], obesity[10][41], and quality-of-life[19] studies
have all relied on self-reported physical activity and often reported weak or null
associations. Such findings have sometimes been interpreted as evidence that
increasing physical activity has limited causal relevance for these endpoints. Our
results suggest an alternative, more parsimonious, explanation: imprecision in the
exposure's measurement may dominate the error structure of these analyses. These
masked effects are consistent with experimental and mechanistic[42] evidence from
RCT's with intermediate outcomes[43], showing increased physical activity improves
vascular function, autonomic balance, and cardiometabolic profiles relevant to CVD
risk.

By holding the causal framework constant and varying only the exposure
assessment method, our study demonstrates that the ability of a target trial
emulation to detect a protective effect can depend critically on how the intervention is
operationalised. Notably, the null findings we observed with self-reported physical
activity persisted despite substantially higher statistical power, indicating that
increased sample size and number of events cannot compensate for poor exposure
measurement. They also persisted after matching the self-reported sample to the
wearables sample on lifestyle, demographic, and health characteristics. In contrast,
wearable-derived physical activity, which captures movement continuously across
the full intensity spectrum with high temporal resolution, produced clearly separated
cumulative risk curves and effect estimates consistent with established biological
plausibility[44-47] and prior evidence[48-51].

Taken together, our results have direct implications for the evaluation of physical
activity guidelines as an intervention concept. As target trial emulation methods are
increasingly applied to observational datasets, in situations where traditional RCTs
maybe less feasible, to inform clinical and public health policy, there is a risk that

reliance on self-reported exposure data may systematically underestimate the
benefits of physical activity, potentially contributing to misguided conclusions about
its effectiveness. Objective exposure assessment should therefore be viewed not as
a methodological refinement but as a prerequisite for valid causal inference in this
context.

Strengths of our study include the explicit target trial specification, the use of repeat
exposure assessments to emulate intervention adoption, the direct comparison of
self-reported and wearable-based physical activity within the same causal
framework, and robust outcome ascertainment through linked health records. This
framework allowed us to empirically isolate the impact of exposure measurement on
causal estimates, an issue that has been widely discussed but rarely demonstrated.
The study design, together with the supplemental and sensitivity analyses in the
wearables sample, consistently showed risk differences, underscoring the stability of
our observed protective association. Limitations of our study include the limited
representativeness of the UK Biobank cohort and the smaller sample size and
shorter follow-up in the wearable subgroup, although these factors did not prevent
detection of clear and clinically meaningful risk differences. We defined intervention
status at re-examination, which may not fully capture long-term maintenance of
guideline-level activity and could contribute to attenuation of the associations. As
with all observational and target trial emulation studies, residual confounding cannot
be fully excluded despite extensive matching on lifestyle, demographic, and clinical
factors and our negative control analysis. However, any such residual confounding
was unlikely to explain the differences between self report and wearables based
analyses, since both analyses incorporated the same set of confounders.

Conclusions

In our target trial emulation, causal estimates for the association between physical
activity and cardiovascular disease differed fundamentally according to exposure
measurement method. Wearable-derived physical activity revealed robust protective
emulated effects, whereas self-reported measures yielded null findings. These
results indicate that imprecise exposure assessment can substantially increase the
risk of Type II error in target trial emulation studies, obscuring true intervention
effects. Future target trial emulations of physical activity should prioritise objective,
device-based exposure assessment to enhance valid causal inference and to avoid

potentially misleading evidence shaping future physical activity guidelines, public
health policy, and clinical practice.

Data Resource: This research was done using the UK Biobank,

a major biomedical database, under application 25813. Data is available upon
application to the UK Biobank.

Acknowledgement: The authors thank all of the participants and professionals
contributing to the UK Biobank.

Conflict of Interest: ES is a paid consultant and holds equity in Complement 1, a
US-based company whose products and services relate to cancer prevention
through lifestyle behaviours modification.

Funding: National Heart Foundation (Dr. Ahmadi;
APP107158) and by a National Health and Medical Research
Council Investigator Grants Level 2 and 3 (Dr. Stamatakis; APP1194510,
APP2040907)

References

1. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *American journal of epidemiology* 2016;183(8):758-64.
2. Cribb L, Moreno-Betancur M, Wu Z, et al. Moving beyond the prevalent exposure design for causal inference in dementia research. *The Lancet Healthy Longevity* 2025;6(2)
3. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *British Journal of Sports Medicine* 2020;54(24):1451-62. doi: 10.1136/bjsports-2020-102955
4. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. *JAMA* 2018;320(19):2020. doi: 10.1001/jama.2018.14854
5. Ross R, Chaput JP, Giangregorio LM, et al. Canadian 24-Hour Movement Guidelines for Adults aged 18-64 years and Adults aged 65 years or older: an integration of physical activity, sedentary behaviour, and sleep. *Appl Physiol Nutr Metab* 2020;45(10 (Suppl. 2)):S57-s102. doi: 10.1139/apnm-2020-0467
6. Hernán MA, Dahabreh IJ, Dickerman BA, et al. The target trial framework for causal inference from observational data: why and when is it helpful? *Annals of Internal Medicine* 2025;178(3):402-07.
7. Ding D, Tarp J, Giovannucci E, et al. Causal inference in physical activity epidemiology research: an opportunity for better evidence: BMJ Publishing Group Ltd and British Association of Sport and Exercise Medicine, 2025:963-65.
8. Hernán MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. *Jama* 2022;328(24):2446-47.
9. Anderson AH. Invited commentary: target trial emulation-a call for more widespread use. *Am J Epidemiol* 2025;194(3):659-61. doi: 10.1093/aje/kwae222
10. Li J, Bea JW, LaMonte M, et al. Effects of moderate/vigorous activity on 3-year body composition changes in postmenopausal women: a target trial emulation. *American journal of epidemiology* 2025;194(4):1032-42.
11. Dahabreh IJ, Bibbins-Domingo K. Causal inference about the effects of interventions from observational studies in medical journals. *Jama* 2024;331(21):1845-53.
12. Bakker LJ, Goossens LM, O'Kane MJ, et al. Analysing electronic health records: the benefits of target trial emulation. *Health Policy and Technology* 2021;10(3):100545.
13. Xu W, Lee AL, Lam CLK, et al. Benefits and risks associated with statin therapy for primary prevention in old and very old adults: real-world evidence from a target trial emulation study. *Annals of internal medicine* 2024;177(6):701-10.
14. Scola G, Chis Ster A, Bean D, et al. Implementation of the trial emulation approach in medical research: a scoping review. *BMC Medical Research Methodology* 2023;23(1):186.
15. Ekelund U, Sanchez-Lastra MA, Dalene KE, et al. Dose-response associations, physical activity intensity and mortality risk: A narrative review. *J Sport Health Sci* 2023 doi: 10.1016/j.jshs.2023.09.006 [published Online First: 20230920]
16. Gill JM, Chico TJ, Doherty A, et al. Potential impact of wearables on physical activity guidelines and interventions: opportunities and challenges. *Br J Sports Med* 2023;57(19):1223-25. doi: 10.1136/bjsports-2023-106822 [published Online First: 20230807]
17. Sattler MC, Ainsworth BE, Andersen LB, et al. Physical activity self-reports: past or future? *Br J Sports Med* 2021;55(16):889-90. doi: 10.1136/bjsports-2020-103595 [published Online First: 20210203]
18. Lee IM, Keadle SK, Matthews CE. Fitness Trackers to Guide Advice on Activity Prescription. *JAMA* 2023 doi: 10.1001/jama.2023.19332 [published Online First: 20231009]
19. Nguyen B, Clare P, Mielke GI, et al. Physical activity across midlife and health-related quality of life in Australian women: A target trial emulation using a longitudinal cohort. *PLoS Med* 2024;21(5):e1004384. doi: 10.1371/journal.pmed.1004384 [published Online First: 20240502]

20. Dickerman BA, Giovannucci E, Pernar CH, et al. Guideline-based physical activity and survival among US men with nonmetastatic prostate cancer. *American journal of epidemiology* 2019;188(3):579-86.
21. Chen N, McGee EE, Nethery RC, et al. Guideline-based physical activity and health-related quality of life among prostate cancer survivors: a target trial emulation in the Health Professionals Follow-up Study. *American Journal of Epidemiology* 2025:kwaf117.
22. Ellis K, Kerr J, Godbole S, et al. Hip and Wrist Accelerometer Algorithms for Free-Living Behavior Classification. *Med Sci Sports Exerc* 2016;48(5):933-40. doi: 10.1249/MSS.0000000000000840
23. Yuan H, Chan S, Creagh AP, et al. Self-supervised learning for human activity recognition using 700,000 person-days of wearable data. *NPJ digital medicine* 2024;7(1):91.
24. Collins R. What makes UK Biobank special? *The Lancet* 2012;379(9822):1173-74.
25. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. *Medicine & science in sports & exercise* 2003;35(8):1381-95.
26. Zisou C, Taylor H, Lacey B, et al. Reproducibility and associated regression dilution bias of accelerometer-derived physical activity and sleep in the UK Biobank. *medRxiv* 2025:2025.01. 16.25320679.
27. Ahmadi MN, Nathan N, Sutherland R, et al. Non-wear or sleep? Evaluation of five non-wear detection algorithms for raw accelerometer data. *Journal of Sports Sciences* 2020;38(4):399-404. doi: 10.1080/02640414.2019.1703301
28. Ahmadi MN, Clare PJ, Katzmarzyk PT, et al. Vigorous physical activity, incident heart disease, and cancer: how little is enough? *Eur Heart J* 2022 doi: 10.1093/eurheartj/ehac572 [published Online First: 20221027]
29. Stamatakis E, Biswas R, Koemel N, et al. Dose-response of incidental physical activity against cardiovascular events and mortality. *Circulation (In Press)* 2025
30. del Pozo Cruz B, Ahmadi M, Sabag A, et al. Step accumulation patterns and risk for cardiovascular events and mortality among suboptimally active adults. *Annals of Internal Medicine* 2025
31. Zhang Z, Kim HJ, Lonjon G, et al. Balance diagnostics after propensity score matching. *Ann Transl Med* 2019;7(1):16. doi: 10.21037/atm.2018.12.10
32. Michel J-P, Leonardi M, Martin M, et al. WHO's report for the decade of healthy ageing 2021–30 sets the stage for globally comparable data on healthy ageing. *The Lancet Healthy Longevity* 2021;2(3):e121-e22.
33. Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database of Systematic Reviews* 2021(11)
34. Cashin AG, Hansford HJ, Hernán MA, et al. Transparent reporting of observational studies emulating a target trial—the TARGET statement. *Jama* 2025;334(12):1084-93.
35. Hernán MA, Sauer BC, Hernández-Díaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *Journal of clinical epidemiology* 2016;79:70-75.
36. Pedišić Ž, Bauman A. Accelerometer-based measures in physical activity surveillance: current practices and issues. *British journal of sports medicine* 2015;49(4):219-23.
37. Kim T, Kim H, Kong S, et al. Association between regular moderate to vigorous physical activity initiation following COPD diagnosis and mortality: an emulated target trial using nationwide cohort data. *Chest* 2024;165(1):84-94.
38. Guo F, McGee EE, Chiu YH, et al. Evaluating recommendation-based dietary and physical activity strategies for prostate cancer prevention: a target trial emulation in the Health Professionals Follow-up Study. *Am J Epidemiol* 2025;194(2):449-59. doi: 10.1093/aje/kwae184

39. Werneck AO, Rezende LF, Stubbs B. Effect of physical activity intervention on late-life depressive symptoms: a target trial emulation using two cohort studies. *Journal of Affective Disorders* 2025:119633.
40. Wei J, Lohman MC, Brown MJ, et al. Physical activity initiated from midlife on risk of dementia and cognitive impairment: the Health and Retirement Study. *Journal of the American Geriatrics Society* 2024;72(12):3668-80.
41. Elahy V, Chiu Y-H, Patel AV, et al. Effectiveness of sustained leisure-time physical activity strategies for obesity-related cancer prevention: an emulated target trial in a prospective US cohort. *BMC medicine* 2025;23(1):580.
42. Fiuza-Luces C, Santos-Lozano A, Joyner M, et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. *Nature Reviews Cardiology* 2018;15(12):731-43. doi: 10.1038/s41569-018-0065-1
43. Batrakoulis A, Jamurtas AZ, Metsios GS, et al. Comparative efficacy of 5 exercise types on cardiometabolic health in overweight and obese adults: a systematic review and network meta-analysis of 81 randomized controlled trials. *Circulation: Cardiovascular Quality and Outcomes* 2022;15(6):e008243.
44. Martinez MW, Kim JH, Shah AB, et al. Exercise-induced cardiovascular adaptations and approach to exercise and cardiovascular disease: JACC state-of-the-art review. *Journal of the American College of Cardiology* 2021;78(14):1453-70.
45. Franklin BA, Eijsvogels TM, Pandey A, et al. Physical activity, cardiorespiratory fitness, and cardiovascular health: A clinical practice statement of the American Society for Preventive Cardiology Part II: Physical activity, cardiorespiratory fitness, minimum and goal intensities for exercise training, prescriptive methods, and special patient populations. *American Journal of Preventive Cardiology* 2022:100425.
46. Lavie CJ, Ozemek C, Carbone S, et al. Sedentary Behavior, Exercise, and Cardiovascular Health. *Circulation Research* 2019;124(5):799-815. doi: 10.1161/circresaha.118.312669
47. Ansdell P, Thomas K, Hicks KM, et al. Physiological sex differences affect the integrative response to exercise: acute and chronic implications. *Experimental Physiology* 2020;105(12):2007-21. doi: 10.1113/ep088548
48. Sanchez-Lastra MA, Ding D, Cruz BDP, et al. Joint associations of device-measured physical activity and abdominal obesity with incident cardiovascular disease: a prospective cohort study. *British Journal of Sports Medicine* 2023:bjsports-2023-107252. doi: 10.1136/bjsports-2023-107252
49. Ding D, Nguyen B, Nau T, et al. Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis. *The Lancet Public Health* 2025;10(8):e668-e81.
50. Ahmadi MN, Hamer M, Gill JMR, et al. Brief bouts of device-measured intermittent lifestyle physical activity and its association with major adverse cardiovascular events and mortality in people who do not exercise: a prospective cohort study. *Lancet Public Health* 2023;8(10):e800-e10. doi: 10.1016/s2468-2667(23)00183-4
51. Li Z, Cheng S, Guo B, et al. Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis. *European heart journal* 2025;46(7):649-64.